Axogen Inc
$ 28.33
2.31%
03 Dec - close price
- Market Cap 1,306,644,000 USD
- Current Price $ 28.33
- High / Low $ 28.75 / 27.50
- Stock P/E N/A
- Book Value 2.62
- EPS -0.05
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE -0.02 %
- 52 Week High 29.32
- 52 Week Low 9.22
About
AxoGen, Inc. is a leading medical technology company based in Alachua, Florida, dedicated to the innovation of surgical solutions for the reconstruction and repair of peripheral nerves damaged by injury or trauma. With a proprietary portfolio that includes advanced nerve grafts, conduits, and associated surgical products, AxoGen aims to enhance nerve regeneration and facilitate functional recovery for patients. As a frontrunner in the regenerative medicine arena, the company is well positioned to capitalize on the increasing demand for peripheral nerve repair solutions, thereby driving sustainable growth while significantly improving patient outcomes in this specialized healthcare market.
Analyst Target Price
$30.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-08-05 | 2025-04-30 | 2025-02-25 | 2024-11-07 | 2024-08-08 | 2024-05-02 | 2024-03-05 | 2023-11-07 | 2023-08-07 | 2023-05-09 | 2023-03-14 |
| Reported EPS | 0.12 | 0.12 | -0.02 | 0.07 | 0.07 | 0.05 | -0.06 | -0.06 | 0.01 | -0.03 | -0.1 | -0.03 |
| Estimated EPS | 0.07 | 0.06 | 0.016 | 0.03 | 0.01 | -0.04 | -0.07 | -0.1 | -0.06 | -0.13 | -0.14 | -0.11 |
| Surprise | 0.05 | 0.06 | -0.036 | 0.04 | 0.06 | 0.09 | 0.01 | 0.04 | 0.07 | 0.1 | 0.04 | 0.08 |
| Surprise Percentage | 71.4286% | 100% | -225% | 133.3333% | 600% | 225% | 14.2857% | 40% | 116.6667% | 76.9231% | 28.5714% | 72.7273% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.0583 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | |
|---|---|---|
| Payment Date | None | None |
| Amount | $1.0 | $0.06 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AXGN
2025-11-02 11:34:58
The Schall Law Firm is investigating Axogen, Inc. (NASDAQ: AXGN) on behalf of investors for potential securities law violations. This investigation follows Axogen's announcement on August 25, 2025, that the FDA extended the PDUFA goal date for its Avance® Nerve Graft BLA, causing a more than 9% drop in share price. Investors who suffered losses are encouraged to contact the firm to discuss their rights.
2025-10-29 07:00:00
Axogen, Inc. reported strong financial results for the third quarter of 2025, with revenue up 23.5% to $60.1 million and adjusted EBITDA of $9.2 million. The company raised its full-year revenue guidance to at least 19% growth, or $222.8 million, driven by broad-based growth across all its markets and expanded coverage for nerve repair products. Key business highlights include new position statements from AAHS and ASRM recognizing nerve allografts as standard medical practice, and the anticipated FDA approval of the Avance® Nerve Graft BLA by December 5, 2025.
2025-10-16 18:26:02
This article provides an in-depth AI-driven analysis for Axogen Inc. (NASDAQ: AXGN), highlighting a neutral near-term sentiment with a potential mid-term weakness. It details tactical trading strategies including position, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis indicating support and resistance levels. The report also points out an exceptional short setup with a favorable risk-reward ratio.
2025-10-15 11:04:38
Axogen, Inc. (NASDAQ: AXGN) has announced it will release its financial results for the third quarter of 2025 on Wednesday, October 29, 2025. The company will also host a conference call and webcast to discuss these financial results and provide a business update at 4:30 p.m. ET on the same day.
2025-10-15 11:00:00
Axogen, Inc. announced it will report its 2025 third-quarter financial results on Wednesday, October 29, 2025, before the market opens. Management will host an investor conference call and webcast at 8:00 a.m. ET to discuss the results. Investors can access the live webcast, archived replay, and presentation slides on the company's Investors page.
2025-10-15 07:43:57
This article details the projected growth of the Nerve Repair Biomaterials Market, which is expected to reach a high CAGR during the forecast period of 2024-2031. It highlights recent industry developments in the United States and Japan, including new product launches and acquisitions by key players like Axogen Inc. and Integra LifeSciences. The report also outlines market segmentation, regional analysis, and offers insights for stakeholders.
